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OBJECTIVE: To evaluate Health Related Quality of Life
(HRQoL) of schizophrenic patients on antipsychotic
treatment. METHODS: A total of 1847 schizophrenic
outpatients who initiated or altered their antipsychotic
treatment were observed for one year. HRQoL was eval-
uated using the EQ-5D questionnaires at baseline, 3, 6
and 12-month intervals. Depending on their treatment
two cohorts were established: patients starting on Olan-
zapine (1091, 59.1%) and patients on other medicines
(756, 40.9%; of which 187 were on Quetiapine, 471 on
Risperidone and 98 on typical antipsychotics). RESULTS:
A total of 64% of subjects were male, mean age 38.9 (13)
with 58.1% under 40. 20.3% were employed and 39.4%
unemployed. The ﬁrst presentation for schizophrenia was
at approximately 28 (10) years. 28.7% had attempted
suicide on one occasion. On ﬁrst visit, 76.4% were 
on antipsychotic treatment. At base point, 91.1% of
patients presented problems in EQ-5D dimensions:
anxiety/depression (75.3%) and usual activity (72.2%),
self-care (45%), pain/discomfort (44.5%) and mobility
(34.6%). The visual analogue scale (VAS) at base point
EQ-5D was 49.7 (19) points. All patients experienced
improvements in quality of life, with differences observed
between both cohorts (p < 0.01). The VAS score for
patients on Olanzapine, went from 49 (19) at base point
to 69 (17) points after 12 months, while the other treat-
ment group increased from 50 (17) to 65 (17) points: an
increased of 19 (21) for Olanzapine and 15 (21) for other
medicines, (p < 0.01). In terms of problems relating to
EQ-5D dimensions, there was a decrease from 92.8% 
to 59.4% in the Olanzapine cohort and from 88.5% to
69.9% in other group after one year of study (p < 0.01).
CONCLUSIONS: The HRQoL of schizophrenic patients
improved after one year with antipsychotic treatment,
with a greater improvement after starting on Olanzapine
compared to other treatments, reducing the percentage 
of patients with problems and improving their state of
health.
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OBJECTIVES: Indwelling urinary catheters are placed in
up to 25% of hospitalized patients and are a leading cause
of hospital-acquired infection. Duration of catheteriza-
tion is the dominant risk factor for hospital-acquired
urinary tract infection (UTI). We have previously shown
that physicians are often unaware that their patients have
a urinary catheter in place, and that these “forgotten”
catheters are frequently unnecessary. We sought to reduce
the duration of urinary catheterization through the use 
of a written reminder placed on the patient’s chart.
METHODS: This before-and-after study with concurrent
control groups occurred on four hospital wards at an aca-
demic medical center. We designed a simple written
reminder that aided the hospitalized patient’s team in
remembering that their patient had a urinary catheter.
Two of the four wards were assigned at random to the
intervention group (where the reminder would be used);
the other two wards served as controls. Bivariable analy-
sis was followed by multivariable Poisson regression
analyses using the number of catheter days as the depen-
dent variable. RESULTS: A total of 5678 subjects were
evaluated. The catheter reminder signiﬁcantly reduced the
proportion of days in which a catheter was present (0.32
for the control wards versus 0.13 for the intervention
wards; p < 0.001). Additionally, 41% of control patients
had a catheter placed, compared to 18% of the patients
on the intervention wards (p < 0.001). In the Poisson
analyses, the overall rate of days in which a catheter was
present was reduced by 35% in the intervention wards 
(p < 0.01). CONCLUSIONS: Catheter-related UTI is a
common, costly, and morbid complication of hospital-
ization. Evidence from our study indicates that a written
reminder that a patient has a urinary catheter decreases
the rate of catheterization, and should thus be considered
as one method for improving the safety of hospitalized
patients.
